Quantcast

Latest Valeant Pharmaceuticals International Inc. Stories

2014-07-18 08:24:42

Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume LAVAL, Quebec, July 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting. The presentation includes a preview...

2014-07-17 08:29:09

VICTUS Platform Offers One of the Largest Arrays of FDA-Cleared Applications for Femto-Assisted Cataract and Refractive Surgery LAVAL, Quebec, July 17, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS(®) Femtosecond Laser Platform for laser-assisted lens fragmentation* during cataract...

2014-07-14 08:26:41

LAVAL, Quebec, July 14, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN). About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty...

2014-07-10 12:29:53

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma. "We are pleased to complete the divestiture of our products to a company that is...

2014-07-08 08:30:55

LAVAL, Quebec, July 8, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of PreCision Dermatology, Inc. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, and Clindagel. About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty...

2014-06-25 08:30:57

LAVAL, Quebec, June 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced the filing of a preliminary proxy statement for a special meeting of shareholders, at which Valeant shareholders will consider and vote upon, among other things, a proposal to approve the issuance of Valeant common shares in connection with an acquisition of Allergan, Inc. ("Allergan") (NYSE: AGN). Valeant commenced an exchange offer for the common...

2014-06-23 08:28:35

LAVAL, Quebec, June 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that, as promised, it has posted fact-based answers to refute misleading assertions made by Allergan, Inc. (NYSE: AGN) in its June 10(th) presentation. Valeant's presentation is posted at http://valeant.com/about/valeant-allergan. Valeant intends to provide future updates to this document as appropriate. About Valeant Pharmaceuticals International, Inc. Valeant...

2014-06-18 12:32:37

LAVAL, Quebec, June 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30(th) proposal directly to Allergan stockholders. Under the terms of the offer, Allergan stockholders would be able to elect to exchange each of their Allergan shares for $72.00 in cash and 0.83 Valeant common shares, or an amount of...

2014-06-16 08:29:21

LAVAL, Quebec, June 16, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane® Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. "We are pleased to have received marketing clearance from...

2014-06-13 20:21:55

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related